ATP敏感性钾通道开放剂埃他卡林对高原脱习服的影响

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (2): 190-193.

ATP敏感性钾通道开放剂埃他卡林对高原脱习服的影响

崔文玉^1,2, 聂鸿靖¹, 张东祥¹, 肖忠海¹, 张雁芳², 崔建华³, 石永平⁴, 龙超良², 王引虎³, 汪海^1,2

¹军事医学科学院卫生学环境医学研究所,天津 300050;
²军事医学科学院毒物药物研究所,北京 100850;
³解放军第18医院,叶城 844900,新疆;
⁴北京赛德维康医药研究院,北京 100039

收稿日期:2009-11-13 修回日期:2010-01-17 出版日期:2010-02-26 发布日期:2020-09-18
通讯作者: 汪海,男,博士,研究员,博士生导师,研究方向:药理学和病理生理学。Tel: 010-66932651 E-mail: wh9588@yahoo.com.cn王引虎,男,主任医师,研究方向:高原医学。
作者简介:前六名作者对本文的贡献相同。崔文玉,女,学士,高级实验师,研究方向:心血管药理学。Tel: 010-66874608 E-mail: cuiwenyu123@yahoo.com.cn
基金资助:
国家科技重大专项:靶向ATP敏感性钾通道防治高原心脏病创新药物的研究 (2008ZXJ09004-018)

Effects of ATP-sensitive potassium channel opner iptakalim on deacclimatization to high altitude

CUI Wen-yu^1,2, NIE Hong-jing¹, ZHANG Dong-xiang¹, XIAO Zhong-hai¹, ZHANG Yan-fang², CUI Jian-hua³, SHI Yong-ping⁴, LONG Chao-liang², WANG Yin-hu³, WANG Hai^1,2

¹ Department of Environmental Medicine, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Tianjin 300050, China;
² Department of Cardiovascular Pharmacology, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China;
³ The 18th Hospital of PLA, Yecheng 844900, Xinjiang, China;
⁴ Beijing Thadweik Academy of Medicine, Beijing 100039, China

Received:2009-11-13 Revised:2010-01-17 Online:2010-02-26 Published:2020-09-18

摘要/Abstract

摘要： 目的:观察长期口服埃他卡林对高原脱习服的影响。方法:该临床研究采用随机双盲安慰剂平行对照试验方法,随机分为埃他卡林试验组和安慰剂对照组,两组受试者分别为39例和17例。其中,受试者分别口服埃他卡林片(5 mg/片,1次/日)或安慰剂(1片/日),连续服用药物7个月,下山到 3700 m 停留 2 d 并停止服药,再返回到海拔 1400 m 的平原地区,自返回平原的第2、4、6天,进行高原脱习服症状调查,随访受试者的高原脱习服症状并进行症状评分。结果:长期驻扎在5200～5380 m 高海拔地区的受试者,返回平原后第2、4、6天,分别有 82.4%、52.9%、23.5%的人员产生显著的高原脱习服症状,长期口服埃他卡林,高原脱习服发生率分别为 43.6%、30.8%、38.5%;安慰剂对照组返回平原后脱习服反应程度的评分,在第2、4、6天分别为(6.0±1.9)、(4.6±1.0)、(3.8±1.5)分,埃他卡林治疗组分别为(4.4±2.4)、(3.3±1.8)、(4.0±1.5)分,两组比较,在返回低海拔第2、4天,高原脱习服反应的发病率及发病程度均显著减少,第6天的数据两组之间差别无统计学意义。结论:高原地区长期口服埃他卡林可显著减轻高原脱习服的发病程度,降低高原脱习服的发生率,预防高原脱习服。

关键词: 高原脱习服, ATP敏感性钾通道开放剂, 埃他卡林

Abstract: AIM: To study the effects of iptakalim, a novel ATP-sensitive potassium channel opner, against deacclimatization to high altitude. METHODS: This study was performed with a randomized, double-blind, placebo-controlled, parallel-group design. Fifty-six male soldiers were randomly divided into two groups: treatment group (39 men) and control group (17 men). The subjects were taken iptakalim tablets (5 mg/tablet, once a day) or placebo(once a day) respectively,for 7 months. The treatment was stopped at the 2 days before the subjects return to 3400 m altitude, and then returned to plain (1400 m). The questionnaire of symptoms of deacclimatization to high altitude was used on the 2nd, 4th, 6th day after the subjects returned to 1400 m altitude and the scores of deacclimatization symptoms were evaluated. RESULTS: Among the 17 men staying at 5200-5380 m high altitude for a long time, the incidences of deacclimatization to high altitude were 82.4%, 52.9% and 23.5% on the 2nd, 4th, 6th day after they returned to 1400 m altitude,respectively. After treated with iptakalim for 7 months, the incidences of deacclimatization were 43.6%, 30.8% and 38.5%,respectively. The scores of deacclimatization symptoms of placebo-control group on the 2nd and 4th,6th day after returning to 1400 m were 6.0±1.9, 4.6±1.0 and 3.8±1.5 respectively, while those in iptakalim-treated group were 4.4±2.4, 3.3±1.8 and 4.0±1.5 respectively. Compared with control, symptoms of deacclimatization to high altitude of treatment group were reduced significantly on the 2nd and 4th day after returning to 1400 m. There was no statistically significant difference in scores of deacclimatization symptoms between the two groups on the 6th day. CONCLUSION: Iptakalim can decrease the incidence of deacclimatization to high altitude, mitigate the symptoms of deacclimatization to high altitude. Iptakalim have a significant effect on prevention and treatment of deacclimatization to high altitude.

Key words: Deacclimatization to high altitude, ATP-sensitive potassium channel opner, Iptakalim

中图分类号:

R188

崔文玉, 聂鸿靖, 张东祥, 肖忠海, 张雁芳, 崔建华, 石永平, 龙超良, 王引虎, 汪海. ATP敏感性钾通道开放剂埃他卡林对高原脱习服的影响[J]. 中国临床药理学与治疗学, 2010, 15(2): 190-193.

CUI Wen-yu, NIE Hong-jing, ZHANG Dong-xiang, XIAO Zhong-hai, ZHANG Yan-fang, CUI Jian-hua, SHI Yong-ping, LONG Chao-liang, WANG Yin-hu, WANG Hai. Effects of ATP-sensitive potassium channel opner iptakalim on deacclimatization to high altitude[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 190-193.

[1]	段瑞峰, 崔文玉, 高红岩, 王小佩, 胡胜凯, 刘卫, 汪海. 血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性[J]. 中国临床药理学与治疗学, 2010, 15(9): 961-966.
[2]	方翼, 王睿, 柴栋, 崔文玉, 汪海, 管华诗. 中国健康成年志愿者单次口服盐酸埃他卡林片耐受性研究[J]. 中国临床药理学与治疗学, 2009, 14(5): 546-550.
[3]	梅宏波, 解卫平, 左祥荣, 王虹. 新型K_ATP开放剂埃他卡林对原代培养人肺动脉平滑肌细胞ERK1/2磷酸化的影响[J]. 中国临床药理学与治疗学, 2009, 14(2): 150-154.
[4]	薛浩, 高敏, 刘国树, 汪海. 盐酸埃他卡林对自发性高血压大鼠肾组织细胞外基质降解系统的影响[J]. 中国临床药理学与治疗学, 2006, 11(10): 1122-1128.
[5]	高敏, 王玉, 汪海. 埃他卡林等三种结构类型的钾通道开放剂对非血管平滑肌舒张作用的选择性[J]. 中国临床药理学与治疗学, 2005, 10(6): 633-636.
[6]	薛浩, 高敏, 刘国树, 汪海. 盐酸埃他卡林对自发性高血压大鼠肾组织K_ATP通道基因表达的影响[J]. 中国临床药理学与治疗学, 2005, 10(5): 489-493.
[7]	柴怡, 丁建花, 李皓, 胡刚. 盐酸埃他卡林对H₂O₂所致PC12细胞损伤的保护[J]. 中国临床药理学与治疗学, 2005, 10(4): 377-381.
[8]	王虹, 解卫平, 汪海, 胡刚. 盐酸埃他卡林对内皮素-1 诱导的大鼠肺动脉高压的影响[J]. 中国临床药理学与治疗学, 2005, 10(1): 9-14.
[9]	龙燕, 杨勇, 丁建花, 胡刚. 新型K_ATP开放剂埃他卡林对氟哌啶醇诱导的大鼠帕金森样症状的影响[J]. 中国临床药理学与治疗学, 2004, 9(4): 378-381.
[10]	贾国栋, 刘国树, 汪海. 盐酸埃他卡林对血管内皮细胞分泌功能的影响[J]. 中国临床药理学与治疗学, 2004, 9(4): 382-385.
[11]	沈红, 王虹, 解卫平, 胡刚. 埃他卡林对长期低氧大鼠肺动脉平滑肌K_ATP mRNA 的影响[J]. 中国临床药理学与治疗学, 2004, 9(4): 389-393.
[12]	王桂英, 龙超良, 汪海. 两种不同结构类型的钾通道开放剂埃他卡林和吡那地尔联合用药降压作用的特征[J]. 中国临床药理学与治疗学, 2004, 9(3): 253-256.
[13]	张颖丽, 汪海. 盐酸埃他卡林对大鼠海马神经元谷氨酸受体功能及突触活动的影响[J]. 中国临床药理学与治疗学, 2004, 9(2): 130-135.
[14]	贾国栋, 崔文玉, 龙超良, 刘国树, 汪海. 新型抗高血压药物盐酸埃他卡林对小动脉的选择性扩张作用及其药理学机制[J]. 中国临床药理学与治疗学, 2004, 9(2): 140-145.
[15]	张颖丽, 冯华松, 汪海. 盐酸埃他卡林对缺氧诱导神经细胞凋亡的影响[J]. 中国临床药理学与治疗学, 2004, 9(1): 20-24.